A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Ozempic may help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits ...

In the second instalment of a two-part feature on captive health insurance in the US, Diana Bui explores how this model can ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.